A group meets for a presentation in a glass-walled conference room, while a woman talks on the phone in the background

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Aug 2022 | From Akero Therapeutics

Normalization of liver fat by efruxifermin is associated with improved liver, adipose tissue, and whole-body metabolic health

Erik Tillman Keystone Symposium on Adipose Tissue and Metabolic Health

Aug 2022 | From Akero Therapeutics

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

Stephen A. Harrison, Peter J. Ruane, Bradley Freilich, Guy Neff, Rashmee Patil, Cynthia Behling, Chen Hu, Reshma Shringarpure, Brittany de Temple, Erica Fong, Erik J. Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale JHEP Reports

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis in NASH patients across PNPLA3 genotypes: a post hoc analysis of the Ph2a BALANCED study

Erik J Tillman, Reshma Shringarpure, Guy Neff, Rashmee Patil, Bradley Freilich, Cynthia Behling, Erica Fong, Brittany de Temple, Kitty Yale, Stephen A Harrison, Tim Rolph The International Liver Congress™ 2022 (EASL)

Jun 2022 | From Akero Therapeutics

Efruxifermin (EFX), a long-acting FGF21 analog as a therapy for NASH

Tim Rolph Keystone Symposium on Tissue Fibrosis and Repair: Mechanisms, Human Disease, and Therapies

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment significantly reduced markers of collagen synthesis and fibrosis and normalized levels of Pro-C3 in patients with livery fibrosis associated with NASH

Erik J Tillman, Louben Dorval, Reshma Shringarpure, Erica Fong, Brittany de Temple, Andrew Cheng, Stephen A Harrison, Kitty Yale, Tim Rolph Keystone Symposium on Tissue Fibrosis and Repair: Mechanisms, Human Disease, and Therapies

Nov 2021 | From Akero Therapeutics

Characterization of Histologic Patterns of Improvement Following Treatment With Efruxifermin (EFX) in NASH Patients With Fibrosis

Behling, C. et al. The Liver Meeting 2021 (AASLD)

Nov 2021 | From Akero Therapeutics

Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats

Tillman, E. Et al. The British Journal of Pharmacology

Jul 2021 | FROM AKERO THERAPEUTICS

Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial

Harrison, S. et al. Nature Medicine

Close up of multichannel micropipette filling four small blue centrifuge tubes

Our comprehensive clinical program is designed to evaluate EFX as a potential treatment for MASH.

View Our Clinical Trials